These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 67893)

  • 1. Phase II study of 5-azacytidine in solid tumors.
    Quagliana JM; O'Bryan RM; Baker L; Gottlieb J; Morrison FS; Eyre HJ; Tucker WG; Costanzi J
    Cancer Treat Rep; 1977; 61(1):51-4. PubMed ID: 67893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of 5-azacytidine in solid tumors.
    Weiss AJ; Metter GE; Nealon TF; Keanan JP; Ramirez G; Swaiminathan A; Fletcher WS; Moss SE; Manthei RW
    Cancer Treat Rep; 1977; 61(1):55-8. PubMed ID: 67894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.
    Carr BI; Rahbar S; Doroshow JH; Blayney D; Goldberg D; Leong L; Asmeron Y
    Cancer Res; 1987 Aug; 47(15):4199-201. PubMed ID: 2440559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of carboplatin (CBDCA) in children with cancer.
    Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
    Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA; Kelly KL
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
    Curt GA; Kelley JA; Fine RL; Huguenin PN; Roth JS; Batist G; Jenkins J; Collins JM
    Cancer Res; 1985 Jul; 45(7):3359-63. PubMed ID: 2408749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of etoposide for carcinoma of the prostate.
    Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
    Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
    Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
    Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
    Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.